2024 Edition Book Updates

This explanation of the question mentions that there are no FDA-approved treatments for metabolic-associated steatohepatitis (MASH). Well, three months after the book's publication, the FDA approved Rezdiffra® (resmetirom) for non-cirrhotic, moderate to severe hepatic scarring.

This question is specifically asking what is the next best step in a patient undergoing lifestyle modifications without success with a BMI of 29 kg/m2. Pharmacotherapy is the best option for her. Pre-diabetes and pre-hypertension do not meet criteria for a comorbidity (for FDA-labeling), but pharmacotherapy can be used (technically off-label) in this patient as it is the most appropriate option, especially compared to the other answer choices. 

Answer choice E is increased heart rate. Patients on bupropion can experience increased heart rate per label, and thus could also be a correct answer. 

Question: A nurse tells a physician that she received a call regarding one of his patients that was not tolerating one of her new blood pressure medications. The patient’s BMI is 46 kg/m2. The physician states, "It's probably because of her weight; patients like her often don't follow medical advice." Which of the following attitudes does this statement reflect?

Change answer B to a 38-year-old with hypertension

Change the "A postpartum female" to  "A female in her second trimester of pregnancy." 

 A human resources representative contacts a manager of a company, stating that one of their employees has encountered a hardship. In the communication, a term is utilized that signifies "an unfair attitude or preconceived notion that can influence how decisions are made about the employee." What term was used? 

Change answer C to "Both the RYGB and bariatric revisions now have percentages in the double digits"  

Change answer D "Abnormality to EKG" to "Abnormality to echocardiogram."

To improve accuracy and prevent confusion, change the phrase in the question stem from " true eating patterns" to " true eating behaviors"    

Wegovy® 2.4 mg has now received an FDA indication for reducing cardiovascular risk (major adverse cardiovascular events, including death, heart attack, or stroke) in those with known cardiovascular disease and overweight or obesity, along with lifestyle changes. [SELECT trial]. This cardiovascular benefit is mentioned in Q 323, but now there is an official FDA indication.